BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines balance Sheet — Total assets ($M) ($M)
Form 10-Q / 10-K Consolidated Balance Sheets (DB)
Latest, Q2 2026
9,176
Period ended Jun 30, 2026
Change on a year earlier
+45.7%
6,298 in Q2 2025
History
43 quarters
Since Q4 2015
Sources
41
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Balance Sheet — Total assets ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 9,176 | +45.7% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 8,554 | +46.4% | Form 10-Q (filed 2026-05-06) ↗ |
| Q4 2025 | Dec 31, 2025 | 8,189 | +38.3% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2025 | Sep 30, 2025 | 7,633 | +30.9% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 6,298 | +10.3% | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 5,842 | +3.1% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 5,921 | +2.0% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2024 | Sep 30, 2024 | 5,831 | +5.5% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 5,712 | -0.3% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 5,668 | -4.9% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 5,805 | -9.0% | Form 10-K (filed 2024-02-26) ↗ |
| Q3 2023 | Sep 30, 2023 | 5,525 | -17.9% | Form 10-Q (filed 2023-11-09) ↗ |
| Q2 2023 | Jun 30, 2023 | 5,729 | -22.4% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 5,957 | -25.7% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2022 | Dec 31, 2022 | 6,379 | -25.3% | Form 10-K (filed 2023-02-27) ↗ |
| Q3 2022 | Sep 30, 2022 | 6,726 | +27.2% | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 7,378 | +33.6% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2022 | Mar 31, 2022 | 8,021 | +37.8% | Form 10-Q (filed 2022-05-09) ↗ |
| Q4 2021 | Dec 31, 2021 | 8,536 | +52.4% | Form 10-Q (filed 2022-11-09) ↗ |
| Q3 2021 | Sep 30, 2021 | 5,286 | -5.0% | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 5,524 | +41.5% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 5,821 | +43.1% | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 5,601 | +247.4% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2020 | Sep 30, 2020 | 5,566 | +195.9% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2020 | Jun 30, 2020 | 3,903 | +81.5% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2020 | Mar 31, 2020 | 4,067 | +87.2% | Form 10-Q (filed 2020-05-11) ↗ |
| Q4 2019 | Dec 31, 2019 | 1,612 | -28.3% | Form 10-K (filed 2020-03-02) ↗ |
| Q3 2019 | Sep 30, 2019 | 1,881 | -21.9% | Form 10-Q (filed 2019-11-12) ↗ |
| Q2 2019 | Jun 30, 2019 | 2,150 | +30.0% | Form 10-Q (filed 2019-08-08) ↗ |
| Q1 2019 | Mar 31, 2019 | 2,172 | +27.1% | Form 10-Q (filed 2019-05-09) ↗ |
| Q4 2018 | Dec 31, 2018 | 2,250 | +115.0% | Form 10-K (filed 2019-02-28) ↗ |
| Q3 2018 | Sep 30, 2018 | 2,409 | +129.6% | Form 10-Q (filed 2018-11-08) ↗ |
| Q2 2018 | Jun 30, 2018 | 1,654 | +248.9% | Form 10-Q (filed 2018-08-09) ↗ |
| Q1 2018 | Mar 31, 2018 | 1,709 | +353.7% | Form 10-Q (filed 2018-05-09) ↗ |
| Q4 2017 | Dec 31, 2017 | 1,047 | +157.9% | Form 10-K (filed 2018-02-28) ↗ |
| Q3 2017 | Sep 30, 2017 | 1,049 | +345.7% | Form 10-Q (filed 2017-11-13) ↗ |
| Q2 2017 | Jun 30, 2017 | 474 | +88.7% | Form 10-Q (filed 2017-08-09) ↗ |
| Q1 2017 | Mar 31, 2017 | 377 | +42.0% | Form 10-Q (filed 2017-05-10) ↗ |
| Q4 2016 | Dec 31, 2016 | 406 | +247.4% | Form 10-K (filed 2017-03-22) ↗ |
| Q3 2016 | Sep 30, 2016 | 235 | – | Form 10-Q (filed 2016-11-10) ↗ |
| Q2 2016 | Jun 30, 2016 | 251 | – | Form 10-Q (filed 2016-08-10) ↗ |
| Q1 2016 | Mar 31, 2016 | 265 | – | Form 10-Q (filed 2016-05-12) ↗ |
| Q4 2015 | Dec 31, 2015 | 117 | – | Form 10-Q (filed 2016-05-12) ↗ |
Breakdown
What makes up balance sheet — total assets ($m)
- Cash and cash equivalents ($M)5,098 · Q2 2026
- Accounts receivable, net ($M)1,056 · Q2 2026
- Inventories, net ($M)733 · Q2 2026
- Total current assets ($M)7,216 · Q2 2026
- Property, plant and equipment, net ($M)1,643 · Q2 2026
- Intangible assets, net ($M)61 · Q2 2026
- Accounts payable ($M)470 · Q2 2026
- Total current liabilities ($M)2,119 · Q2 2026
- Long-term bank loans ($M)882 · Q2 2026
- Total liabilities ($M)4,002 · Q2 2026
- Accumulated deficit ($M)-7,856 · Q2 2026
- Total shareholders' equity ($M)5,174 · Q2 2026
Cite this data
StockData. (2026). BeOne Medicines Balance Sheet — Total assets ($M) ($M), quarterly Q4 2015–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/fs_balance_sheet
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.